Prognostic significance of carotid plaque presence in peritoneal dialysis patients and its association with the apolipoprotein B/apolipoprotein <scp>A1</scp> ratio

Chen, Yun; Shang, Da; Shao, Jie; Dai, Shuqi; Ge, Xiaolin; Hao, Chuan‐Ming; Zhu, Tao

doi:10.1111/nep.13759

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis of patients enrolled in single-center, cross-sectional community-based studies at the University of Pennsylvania found that in Caucasians with type 2 diabetes, plasma apoB, but not LDL-C, may be an indicator of coronary artery calcification beyond traditional risk factors [ 148 ]. The apoB/apoA1 ratio was better than the non-HDL-C/HDL-C ratio in predicting the presence of carotid plaques in patients on peritoneal dialysis [ 149 ]. The apoB/apoA1 ratio also showed improved accuracy over TC/HDL-C in predicting adverse cardiovascular events in a prospective study of patients with established coronary heart disease (CHD) [ 144 ].…”

Section: Biomarkers For Cvd: Ldl-c and Apobmentioning

confidence: 99%

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

et al. 2021

View full text Add to dashboard Cite

Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron remnants with one apoB48 molecule per chylomicron particle. Similarly, a single apoB100 molecule is contained per particle of very-low-density lipoprotein (VLDL), intermediate density lipoprotein, LDL and lipoprotein(a). This unique one apoB per particle ratio makes plasma apoB concentration a direct measure of the number of circulating atherogenic lipoproteins. ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content, which is variable. While LDL, the major cholesterol-carrying serum lipoprotein, is the primary therapeutic target for management and prevention of atherosclerotic cardiovascular disease, there is strong evidence that apoB is a more accurate indicator of cardiovascular risk than either total cholesterol or LDL cholesterol. This review examines multiple aspects of apoB structure and function, with a focus on the controversy over use of apoB as a therapeutic target in clinical practice. Ongoing coronary artery disease residual risk, despite lipid-lowering treatment, has left patients and clinicians with unsatisfactory options for monitoring cardiovascular health. At the present time, the substitution of apoB for LDL-C in cardiovascular disease prevention guidelines has been deemed unjustified, but discussions continue.

show abstract

Section: Biomarkers For Cvd: Ldl-c and Apobmentioning

confidence: 99%

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

et al. 2021

View full text Add to dashboard Cite

show abstract

Peritoneal Dialysis

Fung¹,

Ng²,

Li³

2021

nephsap

View full text Add to dashboard Cite

The Association between Apolipoprotein B, Cardiovascular Risk Factors and Subclinical Atherosclerosis—Findings from the SEPHAR National Registry on Hypertension in Romania

Dorobanţu

Halațiu

Gheorghe‐Fronea

et al. 2023

IJMS

View full text Add to dashboard Cite

The present study aimed to investigate the association between apolipoprotein B (Apo B) and classical features associated with clinical or subclinical atherosclerosis. A total of 811 adult patients from the general Romanian population, included in the national SEPHAR registry on hypertension, were divided into two groups based on Apo B value (low versus high Apo B with a cut-off established at 130 mg/dL) and subsequently into four subgroups according to the cut-offs recommended by the 2021 ESC Guidelines on Cardiovascular Disease Prevention. In all patients, lipid profile, uric acid, full blood count and presence of significant carotid plaques were assessed. Apo B levels were positively correlated with proatherogenic lipids (total cholesterol, triglycerides and LDL-cholesterol, p < 0.0001) and negatively correlated with HDL cholesterol (all p < 0.05). In comparison with patients with low Apo B levels, those with elevated Apo B levels more frequently presented significant carotid plaques (17% vs. 19% vs. 28% vs. 46%, p < 0.0001). Univariate regression analysis identified a strong association between the level of uric acid and increased value of Apo B in the four subgroups (uric acid 4.8 +/− 1.3 vs. 5 +/− 1.6 vs. 5.1 +/− 1.5 vs. 5.8 +/− 1.6, r = 0.2, p < 0.0001). The results of this nationwide registry on hypertension in Romania indicate that high Apo B may be considered as a risk factor for CVD, promoting atherosclerosis and associated with increased expression of classical markers of clinical or subclinical CVD.

show abstract

Prognostic significance of carotid plaque presence in peritoneal dialysis patients and its association with the apolipoprotein B/apolipoprotein A1 ratio

Cited by 3 publications

References 29 publications

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

Peritoneal Dialysis

The Association between Apolipoprotein B, Cardiovascular Risk Factors and Subclinical Atherosclerosis—Findings from the SEPHAR National Registry on Hypertension in Romania

Contact Info

Product

Resources

About